Floatz logo

163 assets in Urothelial Carcinoma

Therapeutic assets addressing Urothelial Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Xmab808
Urothelial Carcinoma
Xencor, Inc.P1CC (42)
[18F]DK222
Urothelial Carcinoma
Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsP1CC (41)
Adrx-0706
Urothelial Carcinoma
Adcentrx TherapeuticsP1CC (41)
Autologous Cd3+ Enriched T Lymphocytes Obtained From Peripheral Blood Mononuclear Cells (Pbmcs) By Apheresis. The Cells Are Transduced With A Self-Inactivating, Non-Replicating Lentiviral Vector Encoding An Enhanced-Affinity T Cell Receptor (Tcr) Targeting The Hla-A*02:01-Restricted Mage-A4 Peptide (Gvydgrehtv) Alongside The Cd8 Alpha (Cd8?) Co-Receptor. The Expressed Transgene Comprises The Coding Sequence For The Cd8? Co-Receptor, Separated By A Foot-And-Mouth Disease Virus 2A Self-Cleaving Peptide Sequence From The Coding Sequence Of The Mage-A4 T-Cell Receptor Alpha And Beta Chains That Are Separated From Each Other By A Porcine Teschovirus-1 2A Self-Cleaving Peptide Sequence, Under Control Of The Human Elongation Factor 1 Alpha (Ef-1?) Promoter. The Construct Is Flanked By 5' And 3' Long Terminal Repeats (Ltrs) And Also Contains A Trna Primer Binding Site, A ? Packaging Signal, A Truncated Gag, A Rev Response Element (Rre) And A Central Polypurine Tract (Cppt) Sequence 5' To The Transgene, And A Polypurine Tract (Ppt) 3' To The Transgene. The Vector Is Pseudotyped With The Vesicular Stomatitis Virus (Vsv) G Envelope Glycoprotein. The Cd3+ T Lymphocytes Are Purified And Activated Using Anti-Cd3/Anti-Cd28 Monoclonal Antibody Coated Magnetic Beads. The Cells Are Then Cultured In Media Containing Interleukin 2 (Il-2), Human Ab Serum And A Protein Kinase B (Akt Inhibitor). The Cells Are Cd3+ (> 80%), Express The High Affinity Mage-A4 Specific Tcr And Cd8? Co-Receptor (Cd8? +Tcr+; >16%) And Are Cytotoxic To Mage-A4 Expressing Tumor Cells
Urothelial Carcinoma
USWM CT, LLCP1CC (41)
ct-202
Urothelial Carcinoma
Context Therapeutics Inc.P1CC (41)
hlx18
Urothelial Carcinoma
Shanghai Henlius BiotechP1CC (41)
ide892
Urothelial Carcinoma
IDEAYA BiosciencesP1CC (41)
MAT2A-IN-9
Urothelial Carcinoma
IDEAYA BiosciencesP1CC (41)
Naptumomab Estafenatox
Urothelial Carcinoma
NeoTX Therapeutics Ltd.P1CC (41)
Obinutuzumab
Urothelial Carcinoma
NeoTX Therapeutics Ltd.P1CC (41)
pds01adc
Urothelial Carcinoma
National Cancer Institute (NCI)P1CC (41)
pf-07265028
Urothelial Carcinoma
PfizerP1CC (41)
pf-07329640
Urothelial Carcinoma
PfizerP1CC (41)
Slv-154
Urothelial Carcinoma
Solve TherapeuticsP1CC (41)
Stro-004
Urothelial Carcinoma
Sutro Biopharma, Inc.P1CC (41)
Zanzalintinib
Urothelial Carcinoma
ExelixisP1CC (41)
Immunotherapic Bifunctional Fusion Protein Comprised Of A Fully Human Igg1 Monoclonal Antibody (Avelumab) Against Human Programmed Death-Ligand 1 (Pd-L1) Fused To The Soluble Extracellular Domain Of Transforming Growth Factor-.Beta. (Tgf-.Beta.) Receptor Ii, Which Acts As A Tgf-.Beta. Trap
Urothelial Carcinoma
National Cancer Institute (NCI)P1CC (40)
aur106
Urothelial Carcinoma
Aurigene Discovery Technologies LimitedP1C (39)
Ava-6000 (Fap-Activated Doxorubicin Prodrug)
Urothelial Carcinoma
Avacta Life Sciences LtdP1C (39)
Bl-M07D1
Urothelial Carcinoma
SystImmune Inc.P1C (39)
Bms-986504
Urothelial Carcinoma
Memorial Sloan Kettering Cancer CenterP1C (39)
Dcc-2812
Urothelial Carcinoma
Deciphera Pharmaceuticals, LLCP1C (39)
dr-0202
Urothelial Carcinoma
Dren BioP1C (39)
Eb-Dt-Nk-Uc101
Urothelial Carcinoma
Beijing BiotechP1C (39)
Etoposide
Urothelial Carcinoma
Jonsson Comprehensive Cancer CenterP1C (39)
Fapi-46
Urothelial Carcinoma
Jonsson Comprehensive Cancer CenterP1C (39)
gen1106
Urothelial Carcinoma
GenmabP1C (39)
H-Gamma1 Heavy Chain Humanized (1-449) [Vh (Homo Sapiens Ighv3-23*01 (81.6%) -(Ighd) -Ighj3*02 (91.7%) M123>T (114), Cdr-Imgt [8.7.13] (26-33.51-57.96-108)) (1-119) -Homo Sapiens Ighg1*03V (100%) G1M3>G1M17, Ng1M1 Ch1 K120, Ch3 E12, M14 (Ch1 R120>K (216) (120-217), Hinge 1-15 (218-232), Ch2 (233-342), Ch3 E12 (358), M14 (360) (343-447), Chs (448-449)) (120-449)], (222-218')-Disulfide With L-Kappa Light Chain Humanized (1'-218') [Vkappa (Homo Sapiens Igkv1-33*01 (87.8%) -Igkj4*01 (100%), Cdr-Imgt [6.3.13] (27'-32'.50'-52'.89'-101')) (1'-111')-Homo Sapiens Igkc*01 (100%) Km3 A45.1, V101 (C-Kappaa45.1 (157'), V101 (195')) (112'-218')]; Dimer (228-228'':231-231'')-Bisdisulfide, Produced In Chinese Hamster Ovary (Cho) Cells, Cell Line Cho-K1, Glycoform Alfa
Urothelial Carcinoma
Genentech, Inc.P1C (39)
hh160
Urothelial Carcinoma
Huahui HealthP1C (39)
Imp-321
Urothelial Carcinoma
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestP1C (39)
Kin-3248
Urothelial Carcinoma
Kinnate BiopharmaP1C (39)
Mnpr-101-Dfo-89Zr
Urothelial Carcinoma
Monopar TherapeuticsP1C (39)
Mnpr-101-Pcta-177Lu
Urothelial Carcinoma
Monopar TherapeuticsP1C (39)
mt-8421
Urothelial Carcinoma
Molecular Templates, Inc.P1C (39)
pf-07820435
Urothelial Carcinoma
PfizerP1C (39)
pf-08046876
Urothelial Carcinoma
PfizerP1C (39)
Phase 1A: Lb-Lr1109
Urothelial Carcinoma
LG ChemP1C (39)
QXL138AM
Urothelial Carcinoma
Nammi Therapeutics IncP1C (39)
RC198
Urothelial Carcinoma
RemeGen Co., Ltd.P1C (39)
Veliparib
Urothelial Carcinoma
National Cancer Institute (NCI)P1C (39)
zm008
Urothelial Carcinoma
Zumutor Biologics Inc.P1C (39)
⁶⁸ga/¹⁷⁷lu-brp-020063
Urothelial Carcinoma
Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineEarly P1C (38)
89zr-lncab072
Urothelial Carcinoma
Affiliated Hospital of Jiangnan UniversityEarly P1C (38)
89zr-lncab103
Urothelial Carcinoma
Affiliated Hospital of Jiangnan UniversityEarly P1C (38)
89zr-lncab104
Urothelial Carcinoma
Affiliated Hospital of Jiangnan UniversityEarly P1C (38)
89zr-lncab190
Urothelial Carcinoma
Affiliated Hospital of Jiangnan UniversityEarly P1C (38)
Anti-Pd-L1 Monoclonal Antibody Ck-301
Urothelial Carcinoma
Checkpoint Therapeutics, Inc.P1C (38)
GA 68
Urothelial Carcinoma
Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineEarly P1C (38)
Fosifloxuridine Nafalbenamide
Urothelial Carcinoma
NuCana plcP1/2C (37)
Cytokine Induced Memory-Like Natural Killer Cells
Urothelial Carcinoma
Dana-Farber Cancer InstituteEarly P1C (36)
Showing 101 to 150 of 163 assets
PreviousPage 3 of 4Next